Purchase this article with an account.
Meidong Zhu, Christine Gaston, Daniel Barthelmes, Mark C. Gillies; Ease Of Cannulating Peripheral Veins In People With Macular Telangiectasia Type II. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4525.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate whether there is a significant difference in venous cannulation difficulty of people with macular telangiectasia type 2 (MacTel) compared with unaffected MacTel family members (MTF) and other patients with macular diseases (OTHER). Furthermore to study, if there is a difference, whether it is disease-related or due to other factors that may cause systemic vascular structure weakness.
Venous cannulations were performed by two individual experienced medical staff on the three groups of the participants. The time taken for the individual cannulation was recorded. The degree of the difficulty including the numbers of attempts was recorded. Other factors that might have influenced ease of venous cannulation, including age, gender, hypertension and diabetic history, body mass index (BMI) and previous cancer treatment, were also analysed.
Thirty-six MacTel patients, 31 MTF members and 14 OTHER patients were included in the study. The time taken to perform venous cannulation were 10-300 seconds (median 25s with inter-quartile 16.25s, MacTel), 5-300 seconds (median 15s with inter-quartile 10s, MTF) and 5-40 seconds (median 10s with inter-quartile 10s, OTHER). Post-hoc test revealed significant differences between MacTel and MTF (P<0.05), MacTel and OTHER (P<0.01). There was no statistically significant difference between MTF and OTHER groups. Risk factor analysis indicated that only the age factor contributed to the difficulty of cannulation.
Venous cannulation is more difficult in people with MacTel compared with the general population with macular disease. Gender, diabetes, history of cancer treatment and BMI did not contribute to the cannulation difficulty. These results suggest that people with MacTel type 2 may also have systemic vascular weakness.
This PDF is available to Subscribers Only